New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
11:48 EDTMYGNMyriad Genetics test predicts response to platinum therapy in triple-negative BC
Myriad Genetics announced that a presentation entitled "Homologous recombination deficiency, HRD, score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer, BC," was presented on Friday, December 7, at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. The study demonstrates that Myriad's HRD test strongly predicts which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer. Triple-negative breast cancer describes breast tumors that lack estrogen receptor, progesterone receptor and HER2. This type of breast cancer tends to be more aggressive than other subtypes of breast cancer and has not been amenable to targeted therapies. The platinum class of drugs kill tumors by causing DNA damage inside the tumor and may be particularly effective against tumors that have lost their ability to repair DNA.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 20, 2015
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 17, 2015
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
March 13, 2015
11:45 EDTMYGNMyriad Genetics management to meet with Stephens
Meeting to be held in Portland, Oregon on March 17-18 hosted by Stephens.
09:49 EDTMYGNUBS life science tools/diagnostics analyst has analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use